依佐加滨对肌萎缩侧索硬化皮质与脊髓运动神经元兴奋性的随机临床试验
这项双盲安慰剂对照2期随机临床试验纳入65例ALS患者,评估依佐加滨600 mg/d或900 mg/d治疗10周对皮质与脊髓运动神经元兴奋性的影响。
要点
- 900 mg/d依佐加滨使ALS患者SICI-1较安慰剂增加53%。
- 600 mg/d组SICI-1较安慰剂无显著变化。
- 依佐加滨呈剂量依赖性降低皮质与脊髓运动神经元兴奋性。
核心结论
- 依佐加滨降低ALS患者皮质与脊髓运动神经元兴奋性,提示神经生理指标可作为多中心临床试验的药效动力学生物标志物。
研究设计与样本
- 参与者按等数量随机分配至依佐加滨600 mg/d、900 mg/d或匹配安慰剂组,治疗10周,并在筛查、基线、第6周和第8周完成现场临床评估与神经生理测量。
关键数值与推荐
- 主要结局为SICI-1从筛查与基线治疗前均值至第6周与第8周全剂量治疗均值的变化。
- 次要结局包括经颅磁刺激测量的皮质运动神经元兴奋性(含静息运动阈值)和阈值追踪神经传导研究测量的脊髓运动神经元兴奋性(含强度-时限时间常数)。
临床怎么用
- 依佐加滨可降低ALS患者皮质与脊髓运动神经元兴奋性,支持将神经生理兴奋性指标用于多中心临床试验的药效动力学评价。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease of the motor nervous system. Clinical studies have demonstrated cortical and spinal motor neuron hyperexcitability using transcranial magnetic stimulation and threshold tracking nerve conduction studies, respectively, although metrics of excitability have not been used as pharmacodynamic biomarkers in multi-site clinical trials. OBJECTIVE: To ascertain whether ezogabine decreases cortical and spinal motor neuron excitability in ALS. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, placebo-controlled phase 2 randomized clinical trial sought consent from eligible participants from November 3, 2015, to November 9, 2017, and was conducted at 12 US sites within the Northeast ALS Consortium. Participants were randomized in equal numbers to a higher or lower dose of ezogabine or to an identical matched placebo, and they completed in-person visits at screening, baseline, week 6, and week 8 for clinical assessment and neurophysiological measurements. INTERVENTIONS: Participants were randomized to receive 600 mg/d or 900 mg/d of ezogabine or a matched placebo for 10 weeks. MAIN OUTCOMES AND MEASURES: The primary outcome was change in short-interval intracortical inhibition (SICI; SICI-1 was used in analysis to reflect stronger inhibition from an increase in amplitude) from pretreatment mean at screening and baseline to the full-dose treatment mean at weeks 6 and 8. The secondary outcomes included levels of cortical motor neuron excitability (including resting motor threshold) measured by transcranial magnetic stimulation and spinal motor neuron excitability (including strength-duration time constant) measured by threshold tracking nerve conduction studies. RESULTS: A total of 65 participants were randomized to placebo (23), 600 mg/d of ezogabine (23), and 900 mg/d of ezogabine (19 participants); 45 were men (69.2%) and the mean (SD) age was 58.3 (8.8) years. The SICI-1 increased by 53% (mean ratio, 1.53; 95% CI, 1.12-2.09; P = .009) in the 900-mg/d ezogabine group vs placebo group. The SICI-1 did not change in the 600-mg/d ezogabine group vs placebo group (mean ratio, 1.15; 95% CI, 0.87-1.52; P = .31). The resting motor threshold increased in the 600-mg/d ezogabine group vs placebo group (mean ratio, 4.61; 95% CI, 0.21-9.01; P = .04) but not in the 900-mg/d ezogabine group vs placebo group (mean ratio, 1.95; 95% CI, -2.64 to 6.54; P = .40). Ezogabine caused a dose-dependent decrease in excitability by several other metrics, including strength-duration time constant in the 900-mg/d ezogabine group vs placebo group (mean ratio, 0.73; 95% CI, 0.60 to 0.87; P < .001). CONCLUSIONS AND RELEVANCE: Ezogabine decreased cortical and spinal motor neuron excitability in participants with ALS, suggesting that such neurophysiological metrics may be used as pharmacodynamic biomarkers in multisite clinical trials. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02450552.
引用
- Wainger BJ, Macklin EA, Vucic S, et al. Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Neurol. 2021. PMID: 33226425. doi:10.1001/jamaneurol.2020.4300
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。